↓ Skip to main content

Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes

Overview of attention for article published in Breast Cancer Research, June 2017
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (52nd percentile)
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

patent
2 patents

Citations

dimensions_citation
71 Dimensions

Readers on

mendeley
100 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Evaluation of invasive breast cancer samples using a 12-chemokine gene expression score: correlation with clinical outcomes
Published in
Breast Cancer Research, June 2017
DOI 10.1186/s13058-017-0864-z
Pubmed ID
Authors

Sangeetha Prabhakaran, Victoria T. Rizk, Zhenjun Ma, Chia-Ho Cheng, Anders E. Berglund, Dominico Coppola, Farah Khalil, James J. Mulé, Hatem H. Soliman

Abstract

A unique 12-chemokine gene expression score (CS) accurately predicted the presence of tumor-localized, ectopic lymph node-like structures (TL-ELNs) and improved overall survival (OS) in primary colorectal cancer and metastatic melanoma. We analyzed the correlation between CS, clinicopathological variables, molecular data, and 366 survival in Moffitt Cancer Center's Total Cancer Care (TCC) patients with non-metastatic breast cancer. Affymetrix gene expression profiles were used to interrogate the CS by the principal component method. Breast tumors were classified as high or low score based on median split, and correlations between clinicopathologic variables, PAM50 molecular subtype, and ELN formation were analyzed using the TCC dataset. Differences in overall survival (OS) and recurrence-free survival (RFS) in the larger KM Plot breast cancer public datasets were compared using Kaplan-Meier curves. We divided the Total Cancer Care (TCC) breast cancer patients into two groups of high or low CS. Mean CS was 0.24 (range, 2.2-2.1). Patients with higher CS were more likely to be white (172 vs. 159; p = 0.03), had poorly differentiated tumors (112 vs. 59; p <0.0001), ER/PR negative (41 vs. 26) and HER2 positive (36 vs. 19; p = 0.001), and contain TL-ELNs. Higher CS scores were also seen in the basal and HER2+ molecular subtypes. In the KM Plot breast cancer datasets higher CS patients demonstrated superior OS (HR = 0.73, p = 0.008) and RFS (HR 0.76, p = <0.0001), especially in basal and HER2+ patients. High CS breast tumors tend to be higher grade, basal or HER2+, and present more frequently in Caucasians. However, this group of patients also shows the presence of TL-ELNs within the tumor microenvironment and has better survival outcomes. The CS is a novel tool that can identify breast cancer patients with tumors of a unique intratumoral immune composition and better prognosis. Whether or not the CS is a predictive response marker in breast cancer patients undergoing immunotherapy remains to be determined.

Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 100 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 100 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 17 17%
Researcher 15 15%
Student > Master 12 12%
Student > Ph. D. Student 10 10%
Student > Doctoral Student 5 5%
Other 10 10%
Unknown 31 31%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 17 17%
Medicine and Dentistry 17 17%
Nursing and Health Professions 7 7%
Immunology and Microbiology 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Other 10 10%
Unknown 38 38%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 10 September 2020.
All research outputs
#8,537,346
of 25,382,440 outputs
Outputs from Breast Cancer Research
#978
of 2,054 outputs
Outputs of similar age
#127,527
of 329,774 outputs
Outputs of similar age from Breast Cancer Research
#16
of 29 outputs
Altmetric has tracked 25,382,440 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,054 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.2. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 329,774 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 52% of its contemporaries.
We're also able to compare this research output to 29 others from the same source and published within six weeks on either side of this one. This one is in the 41st percentile – i.e., 41% of its contemporaries scored the same or lower than it.